GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Artrya Ltd (ASX:AYA) » Definitions » EV-to-EBIT

Artrya (ASX:AYA) EV-to-EBIT : -4.30 (As of May. 25, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Artrya EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Artrya's Enterprise Value is A$80.26 Mil. Artrya's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was A$-18.65 Mil. Therefore, Artrya's EV-to-EBIT for today is -4.30.

The historical rank and industry rank for Artrya's EV-to-EBIT or its related term are showing as below:

ASX:AYA' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.37   Med: 0   Max: 0
Current: -4.31

ASX:AYA's EV-to-EBIT is ranked worse than
100% of 456 companies
in the Healthcare Providers & Services industry
Industry Median: 16.75 vs ASX:AYA: -4.31

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Artrya's Enterprise Value for the quarter that ended in Dec. 2024 was A$41.51 Mil. Artrya's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was A$-18.65 Mil. Artrya's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -44.92%.


Artrya EV-to-EBIT Historical Data

The historical data trend for Artrya's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artrya EV-to-EBIT Chart

Artrya Annual Data
Trend Jun21 Jun22 Jun23 Jun24
EV-to-EBIT
- -1.00 0.15 -0.61

Artrya Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-EBIT Get a 7-Day Free Trial - 0.15 - -0.61 -

Competitive Comparison of Artrya's EV-to-EBIT

For the Health Information Services subindustry, Artrya's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artrya's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Artrya's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Artrya's EV-to-EBIT falls into.


;
;

Artrya EV-to-EBIT Calculation

Artrya's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=80.259/-18.646
=-4.30

Artrya's current Enterprise Value is A$80.26 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Artrya's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was A$-18.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Artrya  (ASX:AYA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Artrya's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 ) =EBIT / Enterprise Value (Q: Dec. 2024 )
=-18.646/41.5094
=-44.92 %

Artrya's Enterprise Value for the quarter that ended in Dec. 2024 was A$41.51 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Artrya's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was A$-18.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Artrya EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Artrya's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Artrya Business Description

Traded in Other Exchanges
N/A
Address
1257 Hay Street, West Perth, Perth, WA, AUS, 6005
Artrya Ltd is a medical technology company. It is engaged in the development and commercialization of Artrya Salix, its patented artificial intelligence platform that detects, diagnoses, and helps address coronary artery disease. The company is managed based on a single segment, being the development of AI-driven CCTA image analysis technology.

Artrya Headlines

No Headlines